Search Results
Mar 24, 2026, 07:00 ET Triquetra Health Launches FolinicActive Kids -- Only USDA Organic Folinic Acid Formula with Multi-Pathway Folate Flexibility, Designed for Children Ages 1-18
enzyme function and is specifically validated in MTHFR 677TT individuals in McNulty et al. (2006, Circulation).* The ages 4–13 dose tier provides 2.5 mg R-5-P, matching the dose studied in that published research."Most parents researching folate for their children encounter two options: folic acid
More news about: Triquetra Health LLC
Mar 24, 2026, 04:45 ET IASO Bio Has Received Clearance from Japan's PMDA to Initiate Clinical Trial for CAR-T Therapy Equecabtagene Autoleucel in Second- or Third-Line Multiple Myeloma
lines of therapy. It is also being developed for use in earlier lines of r/r MM treatment and for autoimmune diseases, including myasthenia gravis (MG), multiple sclerosis (MS), and systemic lupus erythematosus (SLE)/lupus nephritis (LN). Beyond eque-cel, we are developing nine additional therapeutic
More news about: IASO Bio
Mar 24, 2026, 03:43 ET DualityBio (9606.HK) Announces 2025 Annual Results
from patients with Epidermal Growth Factor Receptor mutation ("EGFRm") NSCLC at the ASCO Annual Meeting. As of April 11, 2025, across the 1.5 mg/kg to 6.5 mg/kg dose range in 172 subjects, DB-1310 demonstrated a manageable safety profile, with Grade ≥3 TRAE occurring in 36% of patients and a low treatment-related
More news about: Duality Biotherapeutics, Inc.
Mar 24, 2026, 02:20 ET 映恩生物（9606.HK）公佈2025年度業績
患者的臨床資料，截至 2025 年 4 月 11 日，在 1.5mg/kg 至 6.5mg/kg 劑量範圍內的 172 例受試者中，DB-1310 展現出可控的安全性，≥3 級治療相關不良事件（TRAE）發生率為 36%，在 46 例可評估療效的患者中，uORR 為 43.5%、cORR 為 28.3%、DCR 為 91.3%，mPFS 為 7.03 個月，mOS 為 18.89 個月。2025 年 12 月，在聖安東尼奧乳腺癌研討會上，公司公佈了既往接受過治療的 HR+/HER2 - 乳腺癌患者資料，在接受 5.0-5.5mg/kg 劑量治療的患者中，DB-1310 的 uORR 為 55.6%、cORR
More news about: Duality Biotherapeutics, Inc.
Mar 24, 2026, 01:16 ET GCC Wearable Health Devices Market to Witness 14.7% CAGR, Surpassing USD 3.12 Billion by 2032, Says MarkNtel Advisors
clinically relevant, and data-driven health monitoring solutions. In May 2025, WHOOP introduced its next-generation wearable devices, WHOOP 5.0 and WHOOP MG, featuring advanced capabilities such as ECG monitoring, blood pressure insights, extended 14+ day battery life, and healthspan analytics. This launch
More news about: MarkNtel Advisors
Mar 23, 2026, 20:00 ET The Phase 3 Registration STAR Study of Efdamrofusp Alfa (IBI302) Met its Primary Endpoint, Making it the First Self-developed Extended-interval Treatment for nAMD in China
IB302 8 mg in Chinese participants with nAMD. A total of 600 participants were randomized in a 1:1 ratio to the IBI302 8 mg group and the aflibercept 2 mg group. Both groups received 3 loading doses administered every 4 weeks. After the completion of the loading doses, participants in the IBI302 8 mg group
More news about: Innovent Biologics
Mar 23, 2026, 09:06 ET PLT Launches New Ingredient To Improve Joint Structure, Strength and Function, Promoting Long-Term Mobility
Frankincense (Boswellia serrata). In the recent clinical study, 100 subjects aged 40–75 with Grade II or III osteoarthritis received 200 mg/day of Kinexa or a matching placebo for six months. Assessments occurred at baseline, 1, 2, 4, and 6 months. Key outcomes included WOMAC, VAS, and Lequesne
More news about: PLT Health Solutions
Mar 23, 2026, 07:00 ET Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease
ARIKAYCE 590 mg plusazithromycin 250 mg +ethambutol 15 mg/kg(N=213)Placebo plus azithromycin 250 mg + ethambutol 15 mg/kg (N=212)
More news about: Insmed Incorporated
Mar 23, 2026, 06:59 ET Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD)
a global healthcare company, today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Effexor® SR 37.5 mg / 75 mg capsules (venlafaxine hydrochloride), a serotonin-noradrenaline reuptake inhibitor (SNRI), for the treatment of adults with generalized anxiety disorder
More news about: Viatris Inc.
Mar 22, 2026, 23:14 ET Harbour BioMed Reports the Online Publication of Phase I Results for HBM9378 (SKB378/WIN378), a TSLP-Targeting Antibody
tolerability, pharmacokinetics (PK) and immunogenicity of HBM9378. The dose-escalation study enrolled ten healthy subjects per cohort (20 mg, 60 mg, 200 mg, 600 mg, and 900 mg), with eight receiving HBM9378 and two receiving the placebo at each dose level.Data showed that the incidence of treatment-emergent
More news about: Harbour BioMed
Mar 22, 2026, 20:00 ET Innovent Announces First Participant Dosed of IBI128 (Tigulixostat, XOI) in Phase 3 Clinical Study
enroll 600 Chinese patients who meet the 2015 ACR/EULAR gout diagnostic criteria, and randomize them in a 1:1 ratio to receive tigulixostat 100 mg or febuxostat 40 mg for 24 weeks. The treatment period of the trial was one year. The primary endpoint was the proportion of patients with serum uric acid (sUA)
More news about: Innovent Biologics
Mar 21, 2026, 12:01 ET Circulation Supplements by PureHealth Research Utilize Omega Fatty Acids and Cardiovascular Botanicals to Support Heart Health
these mechanisms through a coordinated product lineup:Complete Omega-3: A daily supplement delivering 1,300 mg EPA and 860 mg DHA per serving to support arterial flexibility and healthy lipid metabolism.Blood Sugar Formula: Combines 17 nutrients,
More news about: PureHealth Research LLC
Mar 20, 2026, 21:53 ET Charlotte's Web Welcomes New CMS Guidance, Advancing Access to Eligible Full‑Spectrum Hemp Products
guidance pages. Under the BEI, CMS has defined eligible hemp products to include orally administered products containing up to 3 mg per serving of tetrahydrocannabinols, a threshold that accommodates non-intoxicating full-spectrum hemp-derived CBD products. This forward‑looking framework
More news about: Charlotte's Web Holdings, Inc.
Mar 20, 2026, 09:03 ET 復宏漢霖2025年業績：收入利潤持續雙增長，體系出海加速落地，創新管線進入密集驗證期
ADC等正在加速佈局。公司成熟商業化品種亦持續貢獻穩定現金流。漢貝泰®（貝伐珠單抗）實現銷售收入3.564億元，同比增長80.8%。基於與合作夥伴的約定，公司就漢利康®（利妥昔單抗）實現銷售及授權許可收入6.117億元，同比增長11.1%；漢達遠®（阿達木單抗）實現銷售及授權許可收入0.592億元，同比增長47.6%。2025年下半年，HLX14（地舒單抗）兩個規格產品分別以BILDYOS®（60mg/mL）和
More news about: 復宏漢霖
Mar 20, 2026, 09:03 ET Henlius Reports 2025 Results: Sustained Growth in Both Revenue and Profit, Advancing Innovation Validation and Global Operations
dosage strengths of HLX14 (denosumab) were approved in the United States, the European Union, and the UK under the trade names BILDYOS® (60 mg/mL) and BILPREVDA® (120 mg/1.7 mL), respectively, and were recently approved in Canada under the trade names BILDYOS® and TUZEMTY®, becoming the first "China-developed"
More news about: Henlius
Mar 20, 2026, 06:02 ET 12 Press Releases You Need to See This Week
a reduced calorie diet and increased physical activity to help adults with obesity lose weight and keep it off, provided they have tolerated the 2.4 mg dosage for at least 4 weeks and additional weight reduction is clinically indicated.Read more of
More news about: PR Newswire
Mar 19, 2026, 13:00 ET Diamond Certified Resource Publishes New Article About Crowd-Sourced Review Sites Being Plagued by Fake and Cherry-Picked Reviews
MG Masonry Inc.
More news about: American Ratings Corporation
Mar 19, 2026, 12:04 ET FDA approves Novo Nordisk's new Wegovy® HD injection, delivering the highest weight loss to date for a Wegovy® injection, adding to its already expansive clinical profile
weight loss, with semaglutide 7.2 mg vs placebo (and for greater than or equal to 20% and 25%, semaglutide 7.2 mg vs semaglutide 2.4 mg).1 In total, 1,407 participants were randomized in a 5:1:1 ratio to receive once-weekly subcutaneous semaglutide 7.2 mg, 2.4 mg, or placebo, alongside lifestyle
More news about: NOVO NORDISK INC.
Mar 19, 2026, 11:35 ET Breckenridge announces launch of Milnacipran HCl Tablets, generic equivalent of Savella®
information including boxed warning, precautions, and adverse reactions.The product is approved for use in adults and is available in 12.5 mg, 25 mg, 50 mg, and 100 mg strengths. Milnacipran HCl Tablets are not approved for use in pediatric patients. Milnacipran HCl Tablets will be manufactured by Breckenridge's
More news about: Breckenridge Pharmaceutical, Inc.
Mar 19, 2026, 10:10 ET Why Your Berberine Failed: RevGenetics Unveils the Absorption Gap Solution
in the small intestine.DiBerberine™ Proprietary Blend (500mg per capsule): This leverages the profound pharmacokinetic advantage of DHB. A 2022 study showed a 100mg dose yielded ~6.7x greater plasma exposure than 500mg of standard berberine HCl.
More news about: RevGenetics
Mar 19, 2026, 09:00 ET ImmunoBrain Presents Clinical Data for First Immune Checkpoint Therapy Approach in Alzheimer's Disease at AD/PD™ 2026
study drug and no cases of amyloid-related imaging abnormalities (ARIA). CSF biomarker analysis (Neurogranin, total-Tau, and pTau181) at a dose of 30 mg/kg of IBC-Ab002, compared to placebo, is concordant with potential synaptic and neuronal protection."There remains a significant unmet need for
More news about: ImmunoBrain Checkpoint Inc.
Mar 19, 2026, 08:02 ET Xyzal® Helps Runners Rise Ready as Official Allergy Sponsor of the 2026 Boston Marathon Presented by Bank of America
Disclaimer: BENADRYL® dosing guide: Adult & Children's Diphenhydramine Dosage. ZYRTEC®Allergy Relief Tables with 10 mg Cetirizine. CLARITIN® Tablets 24-Hour- Relieve Allergy SymptomsMedia contact: Nyaa Ferary,
More news about: Xyzal
Mar 19, 2026, 07:30 ET Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment
BELIEVE study, participants dosed with bimagrumab as monotherapy, achieved reductions in total body fat mass comparable to high-dose semaglutide (2.4 mg) at one year (-25.3% vs. -24.8%, respectively). In the same study, bimagrumab-treated individuals saw a greater reduction in metabolically active visceral
More news about: Biohaven Ltd.
Mar 19, 2026, 06:45 ET Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes
retatrutide initiated treatment with 2 mg once-weekly and increased the dose in a step-wise approach every four weeks until reaching the target dose of 4 mg (via one step at 2 mg), 9 mg (via steps at 2 mg, 4 mg and 6 mg) or 12 mg (via steps at 2 mg, 4 mg, 6 mg and 9 mg).The TRANSCEND-T2D Phase 3 clinical
More news about: Eli Lilly and Company
Mar 18, 2026, 11:22 ET 總生存期顯著延長：蘆康沙妥珠單抗(sac-TMT) OptiTROP-Lung03研究OS最終分析結果亮相
OptiTROP-Lung03研究旨在評估蘆康沙妥珠單抗(sac-TMT)單一療法(5 mg/kg每2週一次) 對比多西他賽，在既往接受過EGFR-TKI和含鉑化療治療的局部晚期或轉移性EGFR突變非小細胞肺癌(NSCLC)患者中的有效性和安全性。此前在2025年ASCO年會上公佈的結果顯示，在137例隨機入組的患者中，相較於多西他賽，蘆康沙妥珠單抗(sac-TMT)在無進展生存期(PFS）和總生存期(OS)方面具有顯著統計學意義和臨床意義的改善——經BICR評估的PFS風險比(HR)為0.30(95%
More news about: 科倫博泰